RCS - Fusion Antibodies - Launch of New Interactive Investor Hub

Fusion AntibodiesAnnouncement

18/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240718:nRSR8211Wa&default-theme=true

RNS Number : 8211W  Fusion Antibodies PLC  18 July 2024

REACH - Non-regulatory announcement*

 

18 July 2024

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Launch of New Interactive Investor Hub

 

Enabling proactive communication and enquiry support to shareholders

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces the launch of its new interactive investor hub which
is accessible from the Company's website.

 

For both existing and prospective shareholders, the new interactive investor
hub brings all of the Company's existing content into a single integrated
platform, and will enable investors and stakeholders to be better informed and
engaged, including but not limited to, the Company's:

 

●     Regulatory announcements

●     Reports

●     Presentations

●     Educational material

●     Interviews

●     Corporate research

 

The new investor hub also offers an interactive online experience, enabling
the Company's stakeholders to comment on and ask the Fusion team questions via
a dedicated portal which the Company will monitor and through which it will
provide appropriate responses in a timely manner.

 

To sign up to the new interactive investor hub, stakeholders are encouraged
to:

 

1.    Visit investorhub.fusionantibodies.com
(https://investorhub.fusionantibodies.com)

2.    Follow the prompts to sign up for an investor hub account

3.    Complete your account profile

 

The information disclosed pursuant to Rule 26 of the AIM Rules for Companies
will continue to be available at the Company's website:
www.fusionantibodies.com (http://www.fusionantibodies.com) .

 

Adrian Kinkaid, CEO of Fusion Antibodies plc, commented: "Engaging with our
shareholders has always been fundamental at Fusion. The launch of our new
interactive investor hub marks an exciting step forward, providing a dynamic
platform for current and potential investors to connect with us as well as to
gain a comprehensive understanding of our mission, our technology and our
business.

 

"The new interactive investor hub will act as a rich resource, offering video
content, detailed information, and insights into our ongoing activities and
future strategies. We encourage our stakeholders to explore the new investor
hub and share their thoughts as we aim to enhance and refine our communication
channels."

 

Enquiries:

 

 Fusion Antibodies plc                                                          www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                             Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                             Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                          Tel: +44 (0) 207 186 9952

 Walbrook PR                       Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                     Mob: +44 (0)7876 741 001

 

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

*About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEDLFFZDLXBBF